Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13)
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC). Materials and Methods Patients whose tumors with EGFR and HER2 overexpression by immunohistochemistry (≥ 1+) were enrolled. Varlitinib and paclitaxel were investigated every 4 weeks. After determining the recommended phase II dose (RP2D) in phase Ib, a phase II study was conducted to evaluate the antitumor activity. Results RP2D was treated with a combination of varlitinib (300 mg twice daily) and paclitaxel. Among 27 patients treated with RP2D, the median progression-free survival and overall survival (OS) were 3.3 months (95% confidence interval [CI], 1.7 to 4.9) and 7.9 months (95% CI, 5.0 to 10.8), respectively, with a median follow-up of 15.7 months. Among 16 patients with measurable disease, the objective response rate (ORR) and disease control rate were 31% and 88%, respectively. Patients with strong HER2 expression (n=8) had a higher ORR and longer OS, whereas those with strong EGFR expression (n=3) had poorer outcomes. The most common adverse events (AEs) of any grade were neutropenia (52%), diarrhea (27%), aspartate aminotransferase/alanine transaminase elevation (22%), and nausea (19%). No treatment-related deaths or unexpected AEs resulting from treatment cessation were observed in patients with RP2D. Conclusion A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.
Abstract
Purpose Varlitinib is a pan-human epidermal growth factor receptor (HER) inhibitor targeting epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and HER4. We present a phase Ib/II study of a combination of varlitinib and weekly paclitaxel as a second-line treatment for patients with EGFR/HER2 co-expressing advanced gastric cancer (AGC). Materials and Methods Patients whose tumors with EGFR and HER2 overexpression by immunohistochemistry (≥ 1+) were enrolled. Varlitinib and paclitaxel were investigated every 4 weeks. After determining the recommended phase II dose (RP2D) in phase Ib, a phase II study was conducted to evaluate the antitumor activity. Results RP2D was treated with a combination of varlitinib (300 mg twice daily) and paclitaxel. Among 27 patients treated with RP2D, the median progression-free survival and overall survival (OS) were 3.3 months (95% confidence interval [CI], 1.7 to 4.9) and 7.9 months (95% CI, 5.0 to 10.8), respectively, with a median follow-up of 15.7 months. Among 16 patients with measurable disease, the objective response rate (ORR) and disease control rate were 31% and 88%, respectively. Patients with strong HER2 expression (n=8) had a higher ORR and longer OS, whereas those with strong EGFR expression (n=3) had poorer outcomes. The most common adverse events (AEs) of any grade were neutropenia (52%), diarrhea (27%), aspartate aminotransferase/alanine transaminase elevation (22%), and nausea (19%). No treatment-related deaths or unexpected AEs resulting from treatment cessation were observed in patients with RP2D. Conclusion A combination of varlitinib and paclitaxel displayed manageable toxicity and modest antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy.
참고문헌 (23)
- Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Kim TH, "Korean Practice Guidelines for Gastric Cancer 2022 : an evidence-based, multidisciplinary approach", J Gastric Cancer, 23, pp.3~106 (2023)
- Koo DH, "Trends in chemotherapy patterns and survival of patients with advanced gastric cancer over a 16-year period : impact of anti-HER2-targeted agent in the real-world setting", Cancer Res Treat, 53, pp.436~444 (2021)
- Hudis CA, "Trastuzumab : mechanism of action and use in clinical practice", N Engl J Med, 357, pp.39~51 (2007)
- Bang YJ, "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA) : a phase 3, open-label, randomised controlled trial", Lancet, 376, pp.687~697 (2010)
- Rha SY, "Breakthroughs in the systemic treatment of HER2-positive advanced", metastatic gastric cancer : from singlet chemotherapy to triple combination, 2023, pp.23, 224~249
- Kim CG, "Trastuzumab combined with ramucirumab and paclitaxel in patients with previously treated human epidermal growth factor receptor 2-positive advanced gastric or gastroesophageal junction cancer", J Clin Oncol, 41, pp.4394~4405 (2023)
- Henjes F, "Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs", Oncogenesis, 1, pp.e16~ (2012)
- Satoh T, "Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations : TyTAN--a randomized, phase III study", J Clin Oncol, 32, pp.2039~2049 (2014)
- Iqbal S, "Southwest Oncology Group study S0413 : a phase II trial of lapatinib(GW572016)as first-line therapy in patients with advanced or metastatic gastric cancer", Ann Oncol, 22, pp.2610~2615 (2011)
- Oh DY, "Phase II trial of dacomitinib in patients with HER2-positive gastric cancer", Gastric Cancer, 19, pp.1095~1103 (2016)
- Martin N, "Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer", Cancer Chemother Pharmacol, 82, pp.979~986 (2018)
- Dokduang H, "In vitro and in vivo anti-tumor effects of pan-HER inhibitor varlitinib on cholangiocarcinoma cell lines", Drug Des Devel Ther, 14, pp.2319~2334 (2020)
- Sierke SL, "Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3(HER3)receptor protein", Biochem J, 322(Pt 3), pp.757~763 (1997)
- Ooi AG, "Varlitinib demonstrates potent antitumor efficacy in patient-derived gastric cancer xenograft models", Cancer Res, 76(14 Suppl), pp.4719~ (2016)
- Liu CY, "Varlitinib downregulates HER", ERK signaling and induces apoptosis in triple negative breast cancer cells, 2019, pp.11, 105~
- Kim J, "664P : phase Iia study to evaluate the biological activity of Aslan001 in Her-1", 2 co-expressing or Her-2 amplified advanced gastric cancer, 2014, pp.25(Suppl 4), iv226~
- Lee MX, "Phase Ib dose-finding study of varlitinib combined with weekly paclitaxel with or without carboplatin +", -trastuzumab in advanced solid tumors, 2022, pp.17, 141~151
- Javle MM, "Varlitinib plus capecitabine in second-line advanced biliary tract cancer : a randomized, phase II study(TreeTopp)", ESMO Open, 7, pp.100314~ (2022)
- Jeong SH, "Practical utility of liquid biopsies for evaluating genomic alterations in castration-resistant prostate cancer", Cancers(Basel), 15, pp.2847~ (2023)
- Wilke H, "Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAIN-BOW) : a double-blind, randomised phase 3 trial", Lancet Oncol, 15, pp.1224~1235 (2014)
- Nakamura Y, "Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers : an emerging paradigm", Nat Rev Clin Oncol, 18, pp.473~487 (2021)
- Lee KS, "Analytical and clinical validation of cell-free circulating tumor DNA assay for the estimation of tumor mutational burden", Clin Chem, 68, pp.1519~1528 (2022)